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AbsTrACT
Objective in order to refine new therapeutic strategies 
in the pipeline for HBV cure, evaluation of virological and 
immunological changes compartmentalised at the site 
of infection will be required. We therefore investigated if 
liver fine needle aspirates (Fnas) could comprehensively 
sample the local immune landscape in parallel with 
viable hepatocytes.
Design Matched blood, liver biopsy and Fnas from 
28 patients with HBV and 15 without viral infection 
were analysed using 16-colour multiparameter flow 
cytometry.
results the proportion of cD4 t, cD8 t, Mucosal 
associated invariant t cell (Mait), natural Killer (nK) 
and B cells identified by Fna correlated with that in 
liver biopsies from the same donors. Populations of 
Programmed Death-1 (PD-1)hicD39hi tissue-resident 
memory cD8 t cells (cD69+cD103+) and liver-resident 
nK cells (cXcr6+t-betloeomeshi), were identified by 
both Fna and liver biopsy, and not seen in the blood. 
crucially, HBV-specific t cells could be identified by 
Fnas at similar frequencies to biopsies and enriched 
compared with blood. Fnas could simultaneously 
identify populations of myeloid cells and live 
hepatocytes expressing albumin, Scavenger receptor 
class B type 1 (Sr-B1), Programmed Death-ligand 1 
(PD-l1), whereas hepatocytes were poorly viable after 
the processing required for liver biopsies.
Conclusion We demonstrate for the first time that 
Fnas identify a range of intrahepatic immune cells 
including locally resident sentinel HBV-specific t cells and 
nK cells, together with PD-l1-expressing hepatocytes. 
in addition, we provide a scoring tool to estimate the 
extent to which an individual Fna has reliably sampled 
intrahepatic populations rather than contaminating 
blood. the broad profiling achieved by this less invasive, 
rapid technique makes it suitable for longitudinal 
monitoring of the liver to optimise new therapies for 
HBV.
InTrODuCTIOn
Chronic hepatitis B virus (HBV) is estimated to 
affect 280 million people worldwide and continues 
to kill more than 700 000 a year.1 Existing antivirals 
can rarely achieve sustained off-treatment responses 
but new therapies are in development, aiming to 
achieve a ‘functional cure’.2 This is defined by Hepa-
titis B Surface Antigen (HBsAg) loss and represents 
the situation where the majority of infection is 
cleared and residual intrahepatic HBV covalently 
closed circular DNA (cccDNA) is kept under tight 
immune control, as seen in adults achieving natural 
resolution. A range of direct-acting antivirals and 
significance of this study
What is already known on this subject?
 ► Many important immune cell types accumulate 
preferentially within the intrahepatic 
compartment.
 ► There are also liver-resident populations of 
NK cells and memory T cells, including HBV-
specific CD8 providing sentinel front-line 
immunosurveillance, that cannot be sampled in 
the blood.
 ► Liver fine needle aspirates (FNAs) have been 
shown to sample intrahepatic immunity, 
including in one case an HBV-specific T cell 
response, but this modality of liver sampling 
has not been widely adopted; whether FNAs 
can be used to investigate tissue-resident T and 
NK cells, and to what extent they recapitulate 
the immune profiles obtained by biopsies, is 
unknown.
 ► FNAs have also been used for flow cytometric 
analysis of HBV-infected hepatocytes; parallel 
analysis of hepatocytes with the immune 
compartment from the same FNA has not been 
reported.
What are the new findings?
 ► Sixteen-colour flow cytometric analysis of 43 
paired FNAs and biopsies reveals that FNAs 
capture all immune cell types tested including 
liver-resident subsets, in a manner that is 
proportionally representative of biopsies.
 ► Analysis of a single cell type (eg, CXCR6+ NK 
cells) can be used to estimate how faithfully 
a given FNA represents the full intrahepatic 
immune spectrum.
 ► FNAs consistently allow analysis of 
intrahepatic HBV-specific CD4 and CD8 T cells, 
and their functionality, making them ideal 
for longitudinal monitoring of novel HBV 
immunotherapies.
 ► Comprehensive immune profiling can be 
combined with hepatocyte phenotyping from 
the same FNA, to optimise analysis of host/
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immunomodulatory approaches are being developed and will 
need careful evaluation as single and combined agents to treat 
patients in different phases of infection.3–6 Thorough virolog-
ical and immunological studies will be required in early phase 
trials of new therapies in order to fully understand their mecha-
nism of action in vivo. This will inform the rational selection of 
biomarkers of responsiveness, the development of drug modi-
fications and selection of combinations. Evaluation of immune 
boosting will clearly be critical for immunomodulatory therapies 
but will also be important in the case of antiviral agents, which 
may indirectly induce some immune reconstitution, for example 
as a result of a reduction in HBV antigen presentation.3 
Although many useful immunological insights into HBV 
pathogenesis have been made by studying peripheral blood, it 
has become increasingly clear that a large proportion of rele-
vant responses are enriched in the liver. In addition, it has 
come to light that tissue-resident immune subsets play vital 
roles in front-line immunosurveillance in the liver and other 
organs; these cannot be sampled in the blood.7–9 We have 
recently shown that a large proportion of HBV-specific CD8 
T cell responses have a tissue-resident phenotype, resulting in 
their compartmentalisation in the liver.7 To achieve functional 
cure of HBV it will be necessary to boost these locally acting 
immune responses, which are adapted to survive the hostile 
liver environment and mount rapid antiviral defence. The liver 
is also enriched with a number of innate-like populations such 
as mucosal associated invariant T (MAIT) cells and natural 
killer (NK) cells; we and others have recently shown that the 
latter also has a specialised liver-resident component.10–14 
In addition to these immunological features unique to the 
liver niche, hepatic sampling also has major advantages over 
peripheral blood for accurately assessing HBV replication, 
integration and cccDNA persistence.5 15–17
Liver biopsy allows a valuable assessment of intrahe-
patic immunological and virological, as well as histological, 
features in HBV infection, but is frequently now replaced 
with non-invasive monitoring.5 Fine needle aspirates (FNAs) 
could provide a rapid and better-tolerated alternative, such 
that repeated longitudinal sampling becomes feasible, as 
recently demonstrated in patients with HCV.18 The use of 
FNA to obtain immune infiltrates or hepatocytes for flow 
cytometric assessment was pioneered in HBV infection by 
the Janssen group more than a decade ago.19 They showed 
that HBsAg-expressing, and less frequently hepatitis B core 
antigen (HBcAg)-expressing, hepatocytes can be detected 
by flow cytometry of FNAs.20 This group also showed that 
an HBV-specific CD8 T cell response directed against the 
core-18–27 epitope could be detected in the FNA from a 
human leucocyte antigen (HLA)-A2+ patient.19 We therefore 
postulated that FNAs are well suited to monitor the intrahe-
patic response to novel therapeutic regimens for HBV infec-
tion. To address this, we compared the capacity of FNAs versus 
biopsies to sample a range of intrahepatic immune cell types, 
particularly focusing on recently defined liver-resident T cell 
and NK cell subsets and other liver-enriched populations such 
as MAIT cells. We showed that HBV-specific T cells directed 
against a panel of epitopes could be detected equally effi-
ciently by FNA or biopsy. Since a concern with FNAs is their 
potential contamination with blood, we evaluated the utility 
of different immune markers to predict how well a sample 
represents the composition of a biopsy and developed this into 
a tool for future studies. In addition, we examined whether it 
was possible to stain immune populations, including myeloid 
cells, and hepatocytes from the same sample, to allow future 




Subjects included in this study were undergoing percutaneous 
liver biopsy for diagnostic purposes; tissue surplus to diagnostic 
requirements was used in tandem to an FNA and blood obtained 
at the same visit. Written informed consent was obtained from all 
patients. Twenty-eight patients with chronic hepatitis B (CHB), 
spanning the disease phases in line with recent international 
guidelines21 were included; envelope Antigen (eAg)-positive 
chronic hepatitis; n=3 (of which one patient sampled on anti-
viral therapy), eAg-negative chronic infection; n=3, eAg nega-
tive chronic hepatitis; n=22 (of which three patients sampled 
on antiviral therapy). In addition 15 patients with non-viral liver 
disease were included. Additional details and clinical character-
istics of patients sampled are included in online supplementary 
methods and supplementary tables S1A,B.
sample collection and cell isolation
For the FNAs, a 22-gauge spinal needle with an internal trocar 
in situ was inserted along the anaesthetised tract to the edge 
of the liver capsule. On expiration the needle was inserted a 
further 2–3 cm into the liver parenchyma. The internal trocar 
was then removed and a 10 mL syringe filled with cold Roswell 
Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich) 
attached to the needle. This was then aspirated with gentle 
negative pressure as the needle was withdrawn 1–2 cm but 
still while remaining in the liver parenchyma using a ‘fanning 
technique’ as previously described in endoscopic ultrasound 
(EUS).22 23 The needle was removed and fresh media drawn into 
the syringe to ensure the entire aspirate passed into the syringe. 
The syringe was detached and the trocar replaced along with 
the needle being inserted through the same anaesthetised tissue 
but orientated in a slightly different direction and the aspira-
tion method repeated as above. The contents of the syringe were 
then promptly passed into a 50 mL Falcon tube containing RPMI 
and placed on ice prior to transfer for processing. Any aspirate 
with frank blood staining was discarded. The liver biopsy was 
then performed immediately afterwards according to previously 
published guidelines.24
Peripheral Blood Mononuclear cells (PBMCs) were isolated 
from heparinised blood by density centrifugation using Pancoll 
(Pan Biotech). Intrahepatic leucocytes (IHLs) from biopsy tissue 
were isolated by mechanical disruption using cell scrapers 
significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► Our findings underscore the value of FNAs as a less invasive 
alternative to liver biopsies, well suited to longitudinal 
monitoring of the intrahepatic immune compartment in 
parallel with hepatocytes.
 ► We derive an algorithm that can be used to ‘score’ FNAs to 
allow their standardisation in clinical studies.
 ► Our data should facilitate the adoption of FNAs in 
early phase trials for the functional cure of HBV as well 
as prompting their reconsideration for flow-cytometric 
monitoring of other liver diseases.
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without further processing (debris removed by passing single cell 
suspension through 70 µM cell strainers (Greiner)). The isola-
tion of IHL from FNA has previously been described.18–20 25 In 
brief, samples were centrifuged; the remaining cell pellet was 
resuspended in 2 mL of red blood cell lysis buffer (Biolegend) for 
5 min on ice, prior to staining. All samples were used immediately.
Flow cytometry and analysis of HbV-specific T cells
Multiparameter flow cytometry was used for phenotypic and 
functional analysis along with detection of HBV-specific T 
cells following dextramer staining or peptide stimulation of 
PBMC and IHL from the FNA and biopsy tissue as previously 
described.7 (For full details of experimental methods see online 
supplementary methods.)
Analytical methods: predictive model
For principal component analysis (PCA), the first dimension 
of the new projection (PC1) contained a linear combination of 
all the measured subset frequencies from the original data set, 
with the coefficients chosen to maximise the variance across this 
dimension. Subsequent Principal Components (PCs) contained 
progressively less of the variance; the first two PCs were visu-
alised in a two-dimensional plot. To model the probability of a 
binary response (ie, whether an FNA sample was more ‘liver-like’ 
or ‘blood-like’) logistic regression was used. Using this approach, 
the probability of the binary response was assumed to be related 
to the input variables using the following equation:
Probability (y)=1/(1+e(β0 +β1 x1 +β2 x2 + …), where y is the 
binary response variable (FNA sample to determine as ‘liver-like’ 
or ‘blood-like’), x1, x2,… are the values of the independent vari-
ables (lymphocytic subset frequencies), and the coefficients β0, 
β1, β2,… are determined from the training data set.
The probability p(y), p(y) e (0,1), was used to predict the 
binary outcome, based on the values of the input variables. 
Finally, each classification model was evaluated in turn using 
bootstrapping. In this approach, a set of ‘n’ selections was made 
from a modified data set containing subset frequencies from the 
biopsy and blood samples only with replacement. The logistic 
regression model was trained using these samples and tested on 
the samples that were not selected, with model accuracy deter-
mined on these test samples being recorded. This process was 
repeated for 1000 iterations to provide confidence intervals 
(CIs) on model accuracy. Once model accuracy was determined, 
the FNA samples were used as an input for the model of choice 
(ie, the best predictive model) to evaluate a probability score of 
how ‘liver-like’ the sampling method was on a patient-by-patient 
basis. All analyses used for data visualisation and the predictive 
modelling were performed using Python. The PCA and logistic 
regression analyses were implemented using scikit-learn, and 
the graphical visualisations were produced using matplotlib and 
seaborn packages.
FnA tool
The equations obtained from the predicative model for frequency 
of CXCR6+ NK cells and/or CD8 TRM (CD69
+CD103+) have 
been used to formulate an ‘FNA tool’ for users to determine how 
‘liver-like’ their FNA sample is. This FNA tool can be accessed 
via the link: http://www. ucl. ac. uk/ maini- group/ software.  
statistical analysis
Statistical analyses were performed in Prism (GraphPad) using 
appropriate methods as indicated in each figure legend. Statis-
tical tests used were the following: Wilcoxon signed-rank t 
test, Mann-Whitney U test, Friedman test (analysis of variance; 
ANOVA) with a Dunn’s post hoc test for pairwise multiple 
comparisons between each group, or a Spearman's rank correla-
tion coefficient. Where significant the differences were marked 
on the appropriate figures. All tests were carried out as two-tailed 
tests and for all tests significance levels were defined as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001.
resulTs
A broad composition of lymphocytes can be obtained by FnA 
sampling
Patients having a diagnostic liver biopsy were invited to simul-
taneously undergo an FNA and venesection. Where surplus 
tissue was available from liver biopsy, this was compared with 
FNAs and peripheral blood from the same time point in a total 
of 43 patients. Using 16-colour flow cytometry we were able 
to analyse a broad composition of lymphocyte subsets (within 
the CD45+ leucocyte gate) including T (CD4 and CD8), MAIT, 
NK and B cells (figure 1A). The frequency of total CD3 T cells 
was not significantly different when comparing blood, FNA and 
liver biopsy (figure 1B). However, as previously reported CD8 
T cells were enriched relative to CD4 T cells within the intra-
hepatic compartment compared with the peripheral CD3 T cell 
pool (figure 1C). This CD8 T cell enrichment was less evident 
in FNAs than in biopsies but their frequencies by these two liver 
sampling methods were significantly correlated (figure 1D). 
Innate-like lymphocytes, in particular MAITs, are now known to 
make up a sizeable proportion of intrahepatic CD3 T cells.26–28 
In a subset of subjects, we therefore analysed MAIT frequencies 
by staining for coexpression of their invariant T cell receptor 
(TCR) Vα7.2 with high CD161 expression (figure 1A,E). MAITs 
were significantly enriched in the liver compartment and we 
observed a striking correlation in frequencies detected within 
an individual by FNA versus biopsy (figure 1E). A similar liver 
enrichment was seen for NK cells (CD3−CD56+), which also 
showed a robust correlation between FNA and biopsy frequen-
cies (figure 1A,F). B cells (CD3−CD19+) showed the converse 
pattern, with lower frequencies in the liver than blood, whether 
sampled by FNA or biopsy, and good congruence between the 
two methods (figure 1A,G).
We then examined whether any differences were detect-
able in the immune composition of FNAs taken from patients 
with HBV infection compared with other liver diseases (online 
supplementary tables S1A,B). We found that the proportion of 
T cells was increased (p=0.007), with a concomitant decrease 
in the percentage of B cells (p=0.018), in HBV compared with 
non-HBV liver disease (figure 1H). These HBV-specific differ-
ences in the hierarchy of different intrahepatic immune cell 
frequencies were detectable in both FNAs and biopsies, vali-
dating the capacity of FNAs to detect novel immunobiological 
features.
liver-resident T cell and nK cell subsets are contained within 
FnAs
Next, we investigated whether it was feasible to use FNAs to study 
specialised tissue-resident T and NK cells that we have recently 
shown are compartmentalised in the liver.7 10 Both FNAs and 
biopsies contained CD8 T cells with a CD69+CD103+ tissue-res-
idency phenotype (CD8 TRM), that were absent from matched 
blood samples; although these were at lower frequencies in FNAs 
(p<0.0001, Wilcoxon test, figure 2A), they were proportional to 
biopsies (figure 2B). Similarly, the CD69 single positive subset, 
which contains a large additional fraction of liver-resident T cells 
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Figure 1 Global lymphocyte profiling of matched blood, FNA and liver biopsy samples. Multiparameter flow cytometric analysis of matched samples 
from blood (blue), FNA (green) and liver biopsy tissue (red) from the same individuals analysed in parallel. (A) Representative sequential gating 
strategy used to identify T cell, NK cell, MAIT cell and B cell subpopulations, pregated on live, singlet CD45 expressing leucocytes. Summary data of 
the frequency of (B) global CD3+ T cells, (C) CD4+ and CD8+ T cells using each sampling method (n=37). (D) Correlation of intrahepatic CD8+ T cell 
frequencies in FNA samples compared with biopsies. Summary frequencies and corresponding correlative analysis of FNA versus biopsy comparing 
intrahepatic populations of (E) MAIT cells (CD3+CD161hiV7.2α+; n=20), (F) NK cells (CD3−CD56+; n=37) and (G) B cells (CD3−CD19+; n=36). (H) 
Summary lymphocyte profiles of blood with corresponding FNA and biopsy comparing HBV-infected patients (n=22) versus non-HBV infected subjects 
(n=14). Error bars indicate means±SEM; p values were determined by a Friedman test (ANOVA) with a Dunn’s post hoc test for multiple comparisons, 
Spearman’s rank correlation coefficient or Mann-Whitney U-test; significant changes marked with asterisks, *p<0.05; **p<0.01; ***p<0.001, 
****p<0.0001. ANOVA, analysis of variance; FNA, fine needle aspirate.
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and some that can recirculate, was enriched in biopsies more 
than FNAs (figure 2A). Despite these discrepancies in frequen-
cies, we found that the CD8 TRM sampled in FNAs showed the 
programmed death-1(PD-1)hiCD39hi phenotype characteristic of 
liver CD8 TRM, with proportions correlating tightly with those 
seen in matched biopsies (figure 2C). These data indicated that 
FNAs can reliably sample prototypic liver CD8 TRM. Neverthe-
less, the fact that CD8 TRM were obtained at lower frequencies in 
FNAs raised the possibility that some may have migrated deeper 
within the liver parenchyma, rendering them only accessible on 
tissue maceration. We therefore compared their expression of two 
liver-homing chemokines which we had shown to be hallmarks 
of liver CD8 TRM; those in FNAs had markedly lower levels of 
CXCR3 and lower levels of CXCR6 than in biopsies (figure 2D).
CXCR6 expression also marks a population of T-betloEomeshi 
liver-resident NK cells that have been shown to be long-lived and 
unable to recirculate.10 14 Frequencies of CXCR6+ NK cells were 
significantly higher, and closely correlated, in FNAs and biopsies 
compared with blood (figure 2E,F). Using the more definitive 
T-betloEomeshi transcription profile, we confirmed that these 
were absent from blood and present in similar proportions in 
FNAs and biopsies (figure 2G).
Figure 2 Identification of liver-resident T cell and NK cell populations by FNA compared with liver biopsy. (A) Representative flow cytometry plots 
depicting non-resident/liver-infiltrating CD8+ T cells (CD69−CD103−), CD69 single positive and liver-resident CD8+ T cells (CD69+CD103+CD8+ TRM) 
in matched blood, FNA and liver biopsy tissue and summary data (n=37) of the frequency of each subset. (B) Correlation of CD8+TRM frequencies in 
FNAs and biopsy samples. (C) Representative histograms of PD-1 and CD39 expression on CD8+TRM versus non-resident subsets and correlation of 
%PD-1 and %CD39 on CD8+TRM in FNAs and biopsies (n=13). (D) Representative histograms of CXCR6 and CXCR3 expression on CD8
+ TRM versus 
non-resident subsets and correlation of their expression on CD8+ TRM in FNAs and biopsies (n=20). (E) Representative plots showing CXCR6
− and 
CXCR6+ fractions of intrahepatic NK cells and summary data of frequency of %CXCR6+ liver-resident NK cells in blood, FNA and liver biopsy (n=32). 
(F) Correlation of CXCR6+ NK cell frequencies in FNAs and biopsies (n=32). (G) Representative plots of T-bet and Eomes expression on CXCR6+ NK 
cells and summary data of the proportion of liver-resident T-betloEomeshi versus liver-infiltrating T-bethiEomeslo NK cells in blood, FNAs and biopsies 
(n=10). Error bars indicate means±SEM; p values were determined by a Friedman test (ANOVA) with a Dunn’s post hoc test for multiple comparisons, 
Wilcoxon signed-rank t test or Spearman’s rank correlation coefficient; significant changes marked with asterisks, *p<0.05; **p<0.01; ***p<0.001, 
****p<0.0001. ANOVA, analysis of variance; FNA, fine needle aspirate.
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Detection of HbV-specific T cells by FnA sampling
To analyse functional HBV-specific CD4 and CD8 T cells at 
the site of infection, we stimulated FNA and biopsy extracts 
with overlapping peptides (OLPs) spanning core and envelope 
proteins and tested for interferon (IFN)-γ responses by intra-
cellular cytokine staining (ICS) (figure 3A). IFN-γ-producing 
HBV-specific CD4 and CD8 T cells were observed at similar, 
and tightly correlated, frequencies in FNA and liver biopsy 
specimens, which tended to be enriched compared with blood 
(figure 3B). We then tested whether FNAs would allow more 
detailed dissection of specificity, by dividing samples into sepa-
rate wells containing OLPs from HBV core, envelope and poly-
merase proteins. There were insufficient events for reliable 
interpretation of individual specificities from either FNA or 
biopsy from patients with high viral loads (online supplementary 
figure S1A). However, a patient with viral load well suppressed 
on antiviral therapy for >5 years had robust CD4 and CD8 T 
cell responses detected against separate core, polymerase and 
envelope peptide pools in both FNA and biopsy samples but not 
blood, illustrating the utility of liver sampling for future immu-
nomonitoring (figure 3C).
Identification of HBV-specific CD8 T cells with a panel of 
HLA-A2/HBV-peptide dextramers has the advantage of allowing 
ex vivo phenotyping. By dividing an FNA and biopsy sample, 
we investigated whether it was possible to use half for ex vivo 
HLA-A2-peptide dextramer analysis and the other for detec-
tion of functional responses by ICS. Stimulation with peptides 
covering the same seven immunodominant HLA-A2-restricted 
epitopes as in the dextramer panel showed similar frequency 
responses detectable by these two methods in a paired FNA and 
biopsy (online supplementary figure S1B,C). Further analysis 
of FNAs and biopsies showed that sufficient HLA-A2-peptide 
dextramer-stained CD8 T cells could be stained (figure 3D) to 
allow assessment of their tissue-residency phenotype using CD69 
±CD103, as described above for global CD8 T cells (figure 3D).7 
Whereas HBV-specific CD8 T cells in the blood had a small 
percentage expressing CD69 and no CD103+CD69+, those in 
FNAs and biopsies were both predominantly single-positive or 
double-positive CD8 TRM, consistent with their compartmental-
isation in the infected liver (figure 3E).
FnA sampling allows simultaneous detection of hepatocytes 
and leucocytes
We next tested the possibility to simultaneously analyse hepato-
cytes in conjunction with lymphocyte or myeloid subsets from 
FNAs. In addition to the classical leucocyte gate set on live 
CD45+ cells, we were able to gate a distinct population of live 
cells with the increased Side Scatter-Area (SSC-A) and lack of 
CD45 expression characteristic of hepatocytes (figure 4A). By 
contrast, the mechanical disruption required to process biopsies 
meant that only a small proportion of cells falling within the 
expected hepatocyte gate were viable (figure 4B). To verify the 
identity of putative hepatocytes in FNA, we showed that they 
expressed scavenger receptor class B type 1 (SR-B1) as well as 
cytokeratin and albumin; in contrast, the CD45+ leucocyte gate 
demonstrated negative expression of these markers (figure 4C). 
We were able to simultaneously identify viable hepatocytes and 
leucocytes in all 10 FNAs where this was attempted; additional 
markers could be included to examine immune cell types of 
interest within the same panel (eg, B cell and T cell stains shown 
in figure 4A). Importantly hepatocytes could also be stained for 
additional markers of relevance to pathogenesis and immuno-
therapy; in all three cases tested it was possible to visualise a 
population of programmed death-ligand 1 (PD-L1)-expressing 
cells restricted to the hepatocyte gate (CD45- albumin+SR-B1+, 
figure 4D).
In addition to using a panel that allowed simultaneous staining 
of hepatocytes and leucocytes, the FNA could be split, with half 
the sample giving adequate cell yields for hepatocyte staining, 
leaving the other half for immunological analyses requiring a 
more extensive antibody staining panel or peptide stimulation 
for HBV-specific T cells (online supplementary tables S1A,B 
and S2). Furthermore, myeloid cells including mononuclear 
phagocyte subsets (classical, intermediate, non-classical)29 30 and 
dendritic cell subsets, broadly divided into plasmacytoid and 
classical,31 could be extracted and identified from FNAs as well 
as from biopsies (gating strategy and representative example 
with summary data of five samples in figure 4E). While a firm 
strategy is yet to be established to identify human liver-resident 
Kupffer cells, it may be possible to identify these in FNAs, as 
suggested by the presence of a CD68+ mononuclear phagocyte 
population at a higher frequency in FNA compared with blood, 
and further enriched in biopsies (figure 4F).
An algorithm to assess FnA sampling of the intrahepatic 
compartment
To test the extent to which immune cell types sampled by FNAs 
contained some representations from blood as well as liver, we 
compared correlations between blood and FNAs or blood and 
biopsies (online supplementary figure S2A). Global CD8 T , 
MAIT , NK  and B cell frequencies in FNAs correlated with 
those in blood (online supplementary figure S2A), as they had 
with matched biopsies (figure 1D–G). More surprisingly, periph-
eral frequencies of MAITs and B cells also correlated convinc-
ingly with those in liver biopsies, suggesting their intrahepatic 
frequencies may be adequately predicted by blood sampling 
(online supplementary figure S2B). By contrast, the very low 
frequencies of cells with a ‘liver-resident’ CD8 T cell profile 
(CD69+CD103+ CD8 TRM) in blood did not correlate with 
proportions found in FNAs or biopsies (online supplementary 
figure S2C). Similarly the low frequency HBV-specific CD8 T 
cell responses detectable in blood did not correlate with frequen-
cies in FNAs or biopsies (online supplementary figure S2D), in 
line with our finding that the latter mainly have a tissue-resi-
dent phenotype, providing useful confirmation of the value of 
liver sampling. CXCR6+ NK cells are mainly sequestered in the 
liver but the small proportion sampled in the blood correlated 
with frequencies in FNAs or biopsies; in contrast T-betloEomeshi 
liver-resident NK cells did not show any correlation between 
blood and FNAs or biopsies, again suggesting that the blood 
cannot accurately sample liver-resident populations (online 
supplementary figure S2E). These findings suggested that blood 
frequencies can be used to estimate intrahepatic frequencies 
of some global immune cell types but not of liver-resident and 
HBV-specific T cells.
A potential concern with liver FNAs is contamination of the 
sample with subcapsular blood or difficulty aspirating some 
highly adherent cell types that may be better sampled by tissue 
maceration. In line with this, FNA sampling underestimated the 
frequencies of some intrahepatic immune populations quanti-
tated in a liver biopsy within the same individual. To make FNAs 
more applicable in the clinical setting, we therefore developed a 
predictive model to enable investigators to assess the reliability 
of an individual FNA at fully representing the immune profile 
that would be expected to be obtained from liver tissue had the 
patient instead had a biopsy.
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Figure 3 Detection of HBV-specific T cell populations in FNA and liver biopsy samples. (A) Representative plots showing the frequency of HBV-
specific CD3+CD4-CD8+ and CD3+CD4+CD8- T cells (%IFN-γ presented minus paired unstimulated control) matched blood, FNA and liver biopsy 
tissue, measured by the production of IFN-γ by ICS following 16 hours stimulation with OLP spanning the core and envelope proteins. (B) Summary 
data of the frequency of HBV-specific CD4 and CD8 T cells (n=8) and their correlation in FNA and biopsy samples. (C) Representative plots showing 
the frequency of HBV-specific CD3+CD4-CD8+and CD3+CD4+CD8- T cells in matched blood, FNA and liver biopsy tissue, measured by the production 
of IFN-γ by ICS following 16 hours stimulation with OLP spanning the core, envelope and polymerase proteins in a virally suppressed patient on 
antiviral therapy (%IFN-γ presented minus paired unstimulated control). (D) Representative plots and summary data (n=6 for blood and FNA; n=5 
for biopsy) of ex vivo staining with a panel of HLA-A2/HBV peptide dextramers (gated using an HLA-A2 restricted control dextramer loaded with 
an irrelevant peptide). (E) Representative plots and summary data (n=5) depicting the proportion of HBV-specific CD8+ T cells identified by ex vivo 
dextramer staining expressing residency markers CD69 and CD103. Circles in summary data depict treatment-naïve patients and squares indicate 
patients analysed during antiviral therapy. Error bars indicate means±SEM; p values were determined by a Wilcoxon signed-rank t test; significant 
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First, we visualised the differences between blood and liver 
biopsy immune profiles using PCA, an exploratory technique 
projecting high dimensional data into a new smaller set of 
dimensions. As expected, this clearly showed that the subset 
composition of blood (blue) and liver (red) samples could be 
distinguished using the two-dimensional projection that PCA 
provides. Investigation of the PC1 weights implied that the 
frequency of the population of liver-resident NK cells drives the 
stratification of samples; PC2 weights are not shown as samples 
could be fully segregated by PC1 alone (figure 5A). We then 
applied logistic regression to build a model allowing separation 
of liver and blood samples (dashed line, figure 5A). The FNA 
data from all available immune parameters could then be super-
imposed onto the PCA to visualise their position according to 
the modelled cut-off (green dots, figure 5B).
To simplify this for routine reproducible longitudinal moni-
toring, we next used bootstrapping to test whether it was 
possible to select a single immune cell parameter on which to 
Figure 4 Using FNA samples to analyse viable hepatocytes and leucocytes in parallel. Representative gating strategy used to distinguish viable 
hepatocytes and leucocytes in the same staining panel using forward and side scatter, a live-dead stain and CD45 in (A) an FNA sample and (B) 
liver biopsy sample. The example shows additional staining for global B (CD19+) and T (CD3+) cells. (C) Representative histograms showing SR-B1, 
cytokeratin and albumin expression, respectively, on hepatocytes (high SSC, CD45−; black open histograms) compared with leucocytes (low SSC, 
CD45+; grey filled histograms). (D) Representative flow cytometry plots of PD-L1 expression on CD45- albumin+SR-B1+hepatocytes compared with 
CD45+ leucocytes by FNA sampling. (E) Representative sequential gating strategy along with summary data (n=5) showing mononuclear phagocyte 
populations in blood, FNA and liver biopsy samples. Pregated on live, singlet CD45+ leucocytes, lineage(CD3,CD19,CD20,CD56,CD66b)− HLA-DR+, 
populations of classical (CD14+CD16−), intermediate (CD14+CD16+) and non-classical (CD14loCD16+) subsets. Populations of dendritic cells (DCs) 
identified as CD14−CD16− populations; pDC (plasmatocytoid DC) identified as CD123+CD11c− and cDC (classical DC) as CD123−CD11c+. (F) Flow 
cytometry plot indicating CD68+ mononuclear phagocyte (pregated on live, singlet, CD45+, HLA-DR+) in blood, FNA and liver biopsy. FNA, fine needle 
aspirate; SSC, side scatter.
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separate liver from blood. Whereas the proportion of total 
NK cells was a poor predictor (59% accuracy), the CD4/CD8 
ratio, which is routinely available in many diagnostic laborato-
ries for HIV monitoring, gave an improved accuracy of 89% 
(figure 5C). However, the use of T cell or NK cell residency 
markers (CXCR6+ NK cells or CD69+CD103+ CD8 TRM 
cells) allowed ~100% accuracy in the prediction of how well 
the intrahepatic compartment had been sampled (figure 5C). 
Using the equation shown or via an ‘FNA tool’ (figure 5C; 
see Materials and methods) investigators can obtain a colour-
coded percentage score for how ‘liver-like' an individual FNA 
sample is. We checked the utility of this tool using a test data set 
of three additional FNA samples not included in the training 
data set. The proportion of CXCR6+ NK cells, and the resulting 
score calculated using the FNA tool, are shown in figure 5D.
DIsCussIOn
In this study, we show that FNAs are able to sample all immune 
cell types tested in the liver, providing a broad and accurate 
profile of intrahepatic immunity. By comparing PBMCs with 
lymphocytes isolated from FNAs and biopsies from the same 
donors, we evaluate how representative FNAs are of the ‘true’ 
liver compartment sampled by biopsies and develop an algo-
rithm for assessing this in future studies. Our data reveal that 
recently defined liver-resident subsets of T cells and NK cells, 
which cannot be sampled in blood, can be reproducibly identi-
fied in both FNAs and biopsies. Importantly, HBV-specific T cell 
responses can be found as reliably in FNAs as in biopsies, using 
either HLA-A2+/peptide multimers or ICS. In FNAs, viable 
hepatocytes can be gated and analysed in the same panel as 
lymphocyte markers, allowing simultaneous analysis of immune/
target cell interactions. Sufficient cells can be obtained from two 
FNA passes for three flow cytometry panels with 16 parame-
ters each, allowing parallel in-depth profiling of immune pheno-
types, virus-specific responses and hepatocyte markers.
While liver biopsies clearly remain the gold standard for intra-
hepatic analysis5 we did not identify any immune cell subset 
that could not be adequately sampled by FNA. We did find that 
FNAs were less ‘liver-like’ in their immune composition than 
biopsies but, importantly, they exhibited a proportional repre-
sentation of all subsets examined. Thus, a particular immune 
response expanded in a biopsy of one individual compared with 
others, was similarly relatively enriched in their FNA. This was 
reflected in the strong and significant correlations seen between 
FNA and biopsy profiles for most parameters examined. Inter-
estingly circulating frequencies of MAITs and B cells correlated 
robustly with those in both FNAs and biopsies, suggesting that 
blood monitoring is reasonably representative of the liver for 
crude numbers of these cell types. However, as expected, the 
blood was not at all representative of intrahepatic frequencies 
of tissue-resident NK cells and T cells, or HBV-specific CD4 and 
CD8 T cells.
We used mathematical modelling to evaluate the utility of 
different parameters to reflect the degree to which an individual 
FNA was representative of the whole immune composition seen 
in a liver biopsy. We found that the routinely measured CD4/8 
T cell ratio could be used alone to evaluate this with approxi-
mately 90% accuracy. However, quantification of the percentage 
of CXCR6+ NK cells brought accuracy up to 100% and could 
be relatively easily incorporated into studies to allow longitu-
dinal standardisation of FNA samples. A further advantage of the 
use of CXCR6+ NK cells for standardisation is that they should 
not be affected by T cell-targeted immunotherapies (unlike the 
CD4/8 T cell ratio or CD69+CD103+ CD8 T cells), one of the 
likely applications of FNA for longitudinal monitoring.
A novel aspect of this study was the demonstration that FNAs 
were capable of sampling tissue-resident subsets of T cells and 
NK cells from the liver. Both of these have been implicated 
as front-line defenders against HBV and are important thera-
peutic targets that cannot be monitored in the blood.7 10 32 The 
CXCR6+ T-betloEomeshi subset of liver-resident NK cells was 
not present at significantly different proportions in FNAs and 
biopsies. This implies that FNAs will constitute a reliable means 
for following the impact of future immunotherapies on both 
Figure 5 Frequencies of CXCR6+ NK cells accurately predict how well an FNA represents the intrahepatic compartment using analytical methods. 
(A) Visualisation of dimension reduction of analysed lymphocyte subsets (global CD4+ T cells, CD8+ T cells, NK cells, B cells, CXCR6±NK cells, and 
CD69+CD103+/CD69+ CD103− CD8 TRM cells), using PCA for blood samples (blue) and liver biopsy samples (red) including PC1 weights. (B) Logistic 
regression identifies the classification boundary that best separates liver from blood (dashed line). FNA samples (green) are projected on to the PCA 
visualisation to determine which side of the boundary they sit. (C) Model accuracy, with 95% CIs shown, obtained by bootstrapping using lymphocytic 
subsets as predictors of how ‘liver-like’ an FNA sample is; the equation used to score accuracy using %CXCR6+ NK cells is shown. (D) Table depicting 
demonstration of the utility of the FNA tool using three additional FNA samples. The proportion of CXCR6+ NK cells, and the resulting score indicates 
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liver-resident and liver-infiltrating components of the NK cell 
response. Efficient FNA sampling of intrahepatic NK cells, even 
the tissue-resident fraction, is in line with their putative intrasi-
nusoidal rather than parenchymal localisation. By contrast, 
CD103+CD69+ CD8 TRM were more abundant in biopsies than 
FNAs, suggesting a fraction of them may have transmigrated 
into the parenchyma from the vasculature, or be tethered more 
firmly to membrane-bound chemokine ligands, and therefore 
less amenable to aspiration. This concept was supported by the 
finding that the expression of the chemokine receptors CXCR6, 
and more strikingly CXCR3, was enriched on CD8 TRM isolated 
from biopsies compared with FNAs. CXCR3 has been shown to 
promote the adhesion of effector cells to hepatic endothelium 
and their subsequent transmigration.33 Although our previous 
limited immunostaining7 and murine studies34 identified hepatic 
CD8 TRM within the vasculature, future multiparameter immu-
nostaining could elucidate whether some migrate into the 
parenchyma.
Despite the differences in frequencies of hepatic CD8 TRM 
isolated by these two sampling methods, their expression of 
PD-1 and CD39 was strongly correlated. Thus prototypic CD8 
TRM with key features thought to underpin their survival in the 
liver niche, were reliably sampled by FNAs. Critically, intrahe-
patic HBV-specific T cells, mostly expressing residency markers 
CD69 ±CD103, were well sampled by FNA and biopsy. This 
reveals the utility of FNA for immune monitoring of patients 
undergoing future treatment trials for HBV cure, since the anal-
ysis of HBV-specific T cells and whether they can be augmented 
at the site of infection will be central to this. Prediction of a 
favourable response to treatment interruption using HBV-spe-
cific CD8 T cell frequencies35 may similarly be enhanced by 
the capacity of FNA to monitor the magnitude, specificity and 
phenotype of responses compartmentalised within the liver. 
Analysis of HBV-specific CD4 and CD8 T cell cytokine produc-
tion will provide useful insights into boosting of local non-cy-
tolytic antiviral capacity, whereas analysis of the therapeutic 
induction of a residency phenotype could inform their likely 
persistence to maintain functional cure.
Flow cytometric analysis of hepatocytes isolated from biop-
sies has been limited by their poor viability following mechanical 
digestion. This limitation is overcome by the use of FNAs, which 
do not require any processing and, we show they can allow 
parallel analysis of hepatocytes and lymphocytes or myeloid cells. 
A remaining concern is the problem of high autofluorescense of 
hepatocytes, requiring careful controls to optimise monoclonal 
antibody (mAb) staining in future studies. It has previously been 
shown that HBV antigens can be stained in hepatocytes from 
FNA;20 our findings pave the way for combining this with the 
analysis of antiviral T cell responses from the same sample, 
allowing ex vivo analysis of virus/host interactions compartmen-
talised within the liver. Our results also exemplify the possibility 
of FNA monitoring of PD-L1 on hepatocytes and/or liver-infil-
trating myeloid cells in conjunction with PD-1 on T cells, for 
example, in the setting of checkpoint blockade trials.
In conclusion, we demonstrate that liver FNAs provide a useful 
alternative to biopsies for monitoring HBV, since they are able to 
concurrently provide a representative profile of key intrahepatic 
immune populations and hepatocytes. Next-generation flow 
cytometers allow around 30 parameters to be stained per well 
and multidimensional analysis techniques will aid visualisation of 
immunotherapy-induced changes in diverse immune cell subsets. 
Such an approach to FNA analysis has already been pioneered by 
Hengst el al, who also showed that immune profiling of FNAs is 
well preserved following their cryopreservation.36 The potential 
to analyse liver-resident HBV-specific T cells will be instrumental 
to the analysis of novel therapeutic combinations and it may 
even prove possible to combine this with cccDNA quantification 
from FNAs. The capacity to use FNAs for longitudinal moni-
toring of responses to therapy has already been demonstrated 
for HCV18 37 and will be an important addition to the assess-
ment of early phase trials in HBV. Finally, our demonstration of 
the potential to study other aspects of immunity, underscores 
the broad applicability of FNAs in the monitoring of other liver 
diseases and infections.
Correction notice this article has been corrected since it published Online First. 
the ’Fna tool’ paragraphic has been updated.
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